Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
BLEX 404 Oral Liquid + Docetaxel in TNBC
NCT02802423Phase 2Not yet recruiting
- Start
- Jan 2027
- Primary completion
- Apr 2028
- Modality
- Botanical drug
01
Overview
A Phase 2 trial of bli-1401 in triple-negative breast cancer (TNBC). Planned start Jan 2027; status: not yet recruiting.
02
Drugs
bli-1401
03
Conditions
triple-negative breast cancer (TNBC)
Beyond the preview
Go deeper on NCT02802423.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02802423.